Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma

por Zhang, Peng-Fei, Gao, Chao, Huang, Xiao-Yong, Lu, Jia-Cheng, Guo, Xiao-Jun, Shi, Guo-Ming, Cai, Jia-Bin, Ke, Ai-Wu
Publicado 2020

Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

por Wang, Si-Wei, Gao, Chao, Zheng, Yi-Min, Yi, Li, Lu, Jia-Cheng, Huang, Xiao-Yong, Cai, Jia-Bin, Zhang, Peng-Fei, Cui, Yue-Hong, Ke, Ai-Wu
Publicado 2022

Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

por Huang, Xiao-Yong, Zhang, Peng-Fei, Wei, Chuan-Yuan, Peng, Rui, Lu, Jia-Cheng, Gao, Chao, Cai, Jia-Bing, Yang, Xuan, Fan, Jia, Ke, Ai-Wu, Zhou, Jian, Shi, Guo-Ming
Publicado 2020

The long noncoding RNA NORAD enhances the TGF‐β pathway to promote hepatocellular carcinoma progression by targeting miR‐202‐5p

por Yang, Xuan, Cai, Jia‐Bin, Peng, Rui, Wei, Chuan‐Yuan, Lu, Jia‐Cheng, Gao, Chao, Shen, Zhao‐Zuo, Zhang, Peng‐Fei, Huang, Xiao‐Yong, Ke, Ai‐Wu, Shi, Guo‐Ming, Fan, Jia
Publicado 2018

Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma

por Wei, Chuan-Yuan, Zhu, Meng-Xuan, Yang, Yan-Wen, Zhang, Peng-Fei, Yang, Xuan, Peng, Rui, Gao, Chao, Lu, Jia-Cheng, Wang, Lu, Deng, Xin-Yi, Lu, Nan-Hang, Qi, Fa-Zhi, Gu, Jian-Ying
Publicado 2019

Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma

por Peng, Rui, Zhang, Peng-Fei, Yang, Xuan, Wei, Chuan-Yuan, Huang, Xiao-Yong, Cai, Jia-Bin, Lu, Jia-Cheng, Gao, Chao, Sun, Hai-Xiang, Gao, Qiang, Bai, Dou-Sheng, Shi, Guo-Ming, Ke, Ai-Wu, Fan, Jia
Publicado 2019

Circular RNA circTRIM33–12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression

por Zhang, Peng-Fei, Wei, Chuan-Yuan, Huang, Xiao-Yong, Peng, Rui, Yang, Xuan, Lu, Jia-Cheng, Zhang, Chi, Gao, Chao, Cai, Jia-Bin, Gao, Ping-Ting, Gao, Dong-Mei, Shi, Guo-Ming, Ke, Ai-Wu, Fan, Jia
Publicado 2019

KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

por Gao, Chao, Wang, Si-wei, Lu, Jia-cheng, Chai, Xiao-qiang, Li, Yuan-cheng, Zhang, Peng-fei, Huang, Xiao-yong, Cai, Jia-bin, Zheng, Yi-min, Guo, Xiao-jun, Shi, Guo-ming, Ke, Ai-wu, Fan, Jia
Publicado 2022

Lymphoid‐specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression

por Yang, Xuan, Miao, Bi‐Si, Wei, Chuan‐Yuan, Dong, Rui‐Zhao, Gao, Ping‐Ting, Zhang, Xin‐Yu, Lu, Jia‐Cheng, Gao, Chao, Wang, Xiao‐Ying, Sun, Hui‐Chuan, Zhou, Jian, Fan, Jia, Ke, Ai‐Wu, Shi, Guo‐Ming, Cai, Jia‐Bin
Publicado 2019

Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma

por Lu, Jia-Cheng, Zhang, Peng-Fei, Huang, Xiao-Yong, Guo, Xiao-Jun, Gao, Chao, Zeng, Hai-Ying, Zheng, Yi-Min, Wang, Si-Wei, Cai, Jia-Bin, Sun, Qi-Man, Shi, Ying-Hong, Zhou, Jian, Ke, Ai-Wu, Shi, Guo-Ming, Fan, Jia
Publicado 2021

Mortalin stabilizes CD151-depedent tetraspanin-enriched microdomains and implicates in the progression of hepatocellular carcinoma

por Liu, Li-Xin, Lu, Jia-Cheng, Zeng, Hai-Ying, Cai, Jia-Bin, Zhang, Peng-Fei, Guo, Xiao-Jun, Huang, Xiao-Yong, Dong, Rui-Zhao, Zhang, Chi, Kang, Qiang, Zou, Hao, Zhang, Xin-Yu, Zhang, Lu, Zhang, Xiao-Wen, Ke, Ai-Wu, Shi, Guo-Ming
Publicado 2019

Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis

por Guo, Xiao-Jun, Huang, Xiao-Yong, Yang, Xuan, Lu, Jia-Cheng, Wei, Chuan-Yuan, Gao, Chao, Pei, Yan-Zi, Chen, Yi, Sun, Qi-Man, Cai, Jia-Bin, Zhou, Jian, Fan, Jia, Ke, Ai-Wu, Shi, Yujiang G., Shen, Ying-Hao, Zhang, Peng-Fei, Shi, Guo-Ming, Yang, Guo-Huan
Publicado 2023

Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma

por Xie, Nan, Cai, Jia-Bin, Zhang, Lu, Zhang, Peng-Fei, Shen, Ying-Hao, Yang, Xuan, Lu, Jia-Cheng, Gao, Dong-Mei, Kang, Qiang, Liu, Li-Xin, Zhang, Chi, Huang, Xiao-Yong, Zou, Hao, Zhang, Xin-Yu, Song, Zheng-Ji, Sun, Hai-Xiang, Fu, Bi-Mang, Ke, Ai-Wu, Shi, Guo-Ming
Publicado 2017

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 stu...

por Shi, Guo-Ming, Huang, Xiao-Yong, Wu, Dong, Sun, Hui-Chuan, Liang, Fei, Ji, Yuan, Chen, Yi, Yang, Guo-Huan, Lu, Jia-Cheng, Meng, Xian-Long, Wang, Xin-Ying, Sun, Lei, Ge, Ning-Ling, Huang, Xiao-Wu, Qiu, Shuang-Jian, Yang, Xin-Rong, Gao, Qiang, He, Yi-Feng, Xu, Yang, Sun, Jian, Ren, Zheng-Gang, Fan, Jia, Zhou, Jian
Publicado 2023

Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors

por Lu, Jia-Cheng, Zeng, Hai-Ying, Sun, Qi-Man, Meng, Qing-Nan, Huang, Xiao-Yong, Zhang, Peng-Fei, Yang, Xuan, Peng, Rui, Gao, Chao, Wei, Chuan-Yuan, Shen, Ying-Hao, Cai, Jia-Bing, Dong, Rui-Zhao, Shi, Ying-Hong, Sun, Hui-Chuan, Shi, Yujiang G., Zhou, Jian, Fan, Jia, Ke, Ai-Wu, Yang, Liu-Xiao, Shi, Guo-Ming
Publicado 2019

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma

por Guo, Xiao-Jun, Lu, Jia-Cheng, Zeng, Hai-Ying, Zhou, Rong, Sun, Qi-Man, Yang, Guo-Huan, Pei, Yan-Zi, Meng, Xian-Long, Shen, Ying-Hao, Zhang, Peng-Fei, Cai, Jia-Bin, Huang, Pei-Xin, Ke, Ai-Wu, Shi, Ying-Hong, Zhou, Jian, Fan, Jia, Chen, Yi, Yang, Liu-Xiao, Shi, Guo-Ming, Huang, Xiao-Yong
Publicado 2021

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

por Meng, Xian-Long, Lu, Jia-Cheng, Zeng, Hai-Ying, Chen, Zhen, Guo, Xiao-Jun, Gao, Chao, Pei, Yan-Zi, Hu, Shu-Yang, Ye, Mu, Sun, Qi-Man, Yang, Guo-Huang, Cai, Jia-Bin, Huang, Pei-Xin, Yv, Lei, Zhang, Lv, Shi, Ying-Hong, Ke, Ai-Wu, Zhou, Jian, Fan, Jia, Chen, Yi, Huang, Xiao-Yong, Shi, Guo-Ming
Publicado 2022